AC
Publications
443
Views
137,456
Downloads
47,922
Supervised works
2
Items per page
1 - 443 of 443
Title Published in Access level OA Policy Year Views Downloads
Mycoplasma genitalium infection in Eswatini amid syndromic case management : prevalence, coinfections, diagnostic challenges and treatment gapsBMC infectious diseases
accessLevelPublic
2025 1 0
HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort StudyClinical infectious diseases
accessLevelPublic
2025 5 10
Low Trauma Fractures in People with HIV : Longitudinal Time Trends in the Swiss HIV Cohort Study 2009-2022Clinical infectious diseases
accessLevelPublic
2025 4 9
Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic PlagueNew England journal of medicine
accessLevelPublic
2025 3 12
Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2025 3 0
Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical DataClinical infectious diseases
accessLevelPublic
2025 1 2
Targeted approaches for acute HIV infection diagnosis in rural EswatiniInternational journal of STD & AIDS
accessLevelPublic
2025 3 8
Enjeux pharmaceutiques autour de la pénicilline G : exemple de la syphilisRevue médicale suisse
accessLevelRestricted
2025 4 0
Tecovirimat at a crossroads : What the PALM007 trial tells usMed
accessLevelRestricted
2025 1 0
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study) : an international survey and Delphi processThe lancet. HIV
accessLevelPublic
2025 3 8
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa : a modelling studyThe lancet. HIV
accessLevelPublic
2025 3 6
Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV : the Swiss HIV Cohort StudyThe journal of infectious diseases
accessLevelPublic
2025 4 6
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025HIV medicine
accessLevelPublic
2025 2 4
Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1PLOS pathogens
accessLevelPublic
2025 4 9
Late Re-Engagement Into HIV Care Among Adults in the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2025 3 0
Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program : A Data Linkage Study of Claims and Swiss HIV Cohort Study DataOpen forum infectious diseases
accessLevelPublic
2025 5 4
Vaccination contre les infections à papillomavirus humains. Indications, couverture et perspectivesRevue médicale suisse
accessLevelRestricted
2025 1 0
Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfectionHIV medicine
accessLevelRestricted
2025 2 0
VIH : ce qui a changé en 2024Revue médicale suisse
accessLevelRestricted
2025 3 0
Leukocyte count and new-onset diabetes mellitus in people with HIV : A longitudinal studyHIV medicine
accessLevelPublic
2025 5 10
Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV : A feasibility surveyHIV medicine
accessLevelPublic
2025 2 2
High Burden of Symptomatic and Asymptomatic Sexually Transmitted Infections in a Routine Decentralised HIV Care Setting in Eswatini : A Cross‐Sectional StudyTM & IH. Tropical medicine and international health
accessLevelPublic
2025 5 11
Retiring the language of first-line and second-line ARTThe lancet. HIV
accessLevelPublic
2025 1 1
Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods studyJournal of clinical epidemiology
accessLevelPublic
2025 2 2
International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreakPLOS global public health
accessLevelPublic
2025 2 1
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaAIDS
accessLevelPublic
2025 1 0
Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease : A European Multicenter Mpox Observational Cohort Study (MOSAIC)Clinical infectious diseases
accessLevelPublic
2025 2 0
Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy designThe journal of experimental medicine
accessLevelPublic
2025 3 5
Predictive risk assessment and targeted testing could enhance STI diagnosis in a high HIV prevalence setting in EswatiniScientific reports
accessLevelPublic
2025 1 0
Low sensitivity of the fourth-generation antigen/antibody HIV rapid diagnostic test Determine™ HIV Early Detect for detection of acute HIV infection at the point of care in rural Eswatini : a diagnostic accuracy studyJournal of the International AIDS Society
accessLevelPublic
2025 3 40
Gender and geographical bias in the editorial decision-making process of biomedical journals : a case-control studyBMJ evidence-based medicine
accessLevelPublic
2024 33 48
External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIVOpen forum infectious diseases
accessLevelPublic
2024 5 12
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort : a prospective observational cohort studyThe lancet. HIV
accessLevelRestricted
2024 86 0
Time Trends in Causes of Death in People With HIV : Insights From the Swiss HIV Cohort StudyClinical infectious diseases
accessLevelPublic
2024 3 4
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine : a multicenter prospective observational study in SwitzerlandThe Lancet regional health. Europe
accessLevelPublic
2024 3 10
Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cellsNature medicine
accessLevelPublic
2024 3 6
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression : Results Through Week 144 of the SIMPL'HIV TrialOpen forum infectious diseases
accessLevelPublic
2024 4 6
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsThe lancet. HIV
accessLevelRestricted
2024 1 0
Characterization and Determinants of Long-Term Immune Recovery Under Suppressive Antiretroviral TherapyJournal of acquired immune deficiency syndromes
accessLevelPublic
2024 3 2
Rendre la recherche clinique plus attractiveRevue médicale suisse
accessLevelRestricted
2024 2 0
Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular RiskOpen forum infectious diseases
accessLevelPublic
2024 1 0
Infectious disease events in people with HIV receiving kidney transplantation : Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort StudyBMC infectious diseases
accessLevelPublic
2024 60 77
Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIVFrontiers in pharmacology
accessLevelPublic
2024 1 1
Novel anti-obesity drugs for people with HIVThe lancet. HIV
accessLevelRestricted
2024 2 0
Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIVClinical infectious diseases
accessLevelPublic
2024 2 10
Cohort profile : the Swiss Mother and Child HIV Cohort Study (MoCHiV)BMJ open
accessLevelPublic
2024 3 4
Patient and public involvement in HIV research : a mapping review and development of an online evidence mapJournal of the International AIDS Society
accessLevelPublic
2024 2 4
Effectively protecting health care workers as clade 1 mpox epidemic complexifies : a call for vaccine and antivirals deploymentJournal of travel medicine
accessLevelPublic
2024 6 4
Self-reported neurocognitive complaints in the Swiss HIV Cohort Study : a viral genome-wide association studyBrain communications
accessLevelPublic
2024 2 4
Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minoritiesHIV medicine
accessLevelPublic
2024 2 10
Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIViScience
accessLevelPublic
2024 1 1
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy : the SIMPL'HIV open-label, factorial randomised controlled trialSwiss medical weekly
accessLevelPublic
2024 3 9
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocolBMC infectious diseases
accessLevelPublic
2024 120 98
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort StudyThe journal of infectious diseases
accessLevelPublic
2024 4 3
Similar Viral and Immune Characteristics of Kaposi Sarcoma in ART-treated People Living With HIV and Older Patients With Classic Kaposi SarcomaOpen forum infectious diseases
accessLevelPublic
2024 3 5
Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir TherapyThe journal of infectious diseases
accessLevelPublic
2024 2 0
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy : 48-week results of a phase 3, randomised, open-label, non-inferiority trialThe lancet. HIV
accessLevelRestricted
2024 1 0
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIVClinical pharmacology and therapeutics
accessLevelPublic
2024 87 76
Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3)The journal of infectious diseases
accessLevelPublic
2024 514 423
Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort StudyLiver international
accessLevelPublic
2024 3 10
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodiesThe journal of experimental medicine
accessLevelPublic
2024 1 0
Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free) : protocol for a multicentre, multistage, randomised, controlled, non-inferiority trialBMJ open
accessLevelPublic
2024 1 0
Trends in Mortality in People With HIV From 1999 through 2020 : A Multicohort CollaborationClinical infectious diseases
accessLevelPublic
2024 4 3
Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trialBMJ open
accessLevelPublic
2024 25 65
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapyHIV medicine
accessLevelPublic
2024 3 5
Mpox : The alarm went off. Have we gone back to sleep ?PLoS neglected tropical diseases
accessLevelPublic
2024 4 0
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1Journal of antimicrobial chemotherapy
accessLevelRestricted
2023 92 0
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral TherapyClinical infectious diseases
accessLevelPublic
2023 100 90
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV) : A Study Combining Modelling and Swiss HIV Cohort DataClinical infectious diseases
accessLevelPublic
2023 113 68
Viral suppression and retention in HIV care during the postpartum period among women living with HIV : a longitudinal multicenter cohort studyThe Lancet regional health. Europe
accessLevelPublic
2023 62 13
VIH : zoom sur les traitements injectables à longue durée d’actionRevue médicale suisse
accessLevelPublic
2023 116 124
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimenBritish journal of clinical pharmacology
accessLevelPublic
2023 103 60
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon : Week 192 Data of the NAMSAL-ANRS-12313 StudyOpen forum infectious diseases
accessLevelPublic
2023 4 8
Mpox in people with advanced HIV infection: a global case seriesLancet
accessLevelPublic
2023 138 272
External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or olderHIV medicine
accessLevelPublic
2023 92 59
Low prevalence of asymptomatic mpox in populations at high riskThe Lancet microbe
accessLevelPublic
2023 116 35
An Automated Literature Review Tool (LiteRev) for Streamlining and Accelerating Research Using Natural Language Processing and Machine Learning: Descriptive Performance Evaluation StudyJMIR. Journal of medical internet research
accessLevelPublic
2023 163 149
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-studyBMC pharmacology & toxicology
accessLevelPublic
2023 59 103
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV CoinfectionClinical infectious diseases
accessLevelRestricted
2023 111 0
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialCritical care
accessLevelPublic
2023 82 44
Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohortHIV medicine
accessLevelPublic
2023 87 124
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort studyAIDS
accessLevelPublic
2023 115 39
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV : The Swiss HIV Cohort StudyThe Journal of infectious diseases
accessLevelPublic
2023 93 31
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)Open forum infectious diseases
accessLevelPublic
2023 88 55
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in SwitzerlandClinical infectious diseases
accessLevelPublic
2023 103 30
A Case of Mpox ReinfectionClinical infectious diseases
accessLevelPublic
2023 73 84
No time for complacency on COVID-19 in EuropeLancet
accessLevelPublic
2023 126 29
The international Unity study for antivirals against mpox is a blueprint for future epidemicsNature medicine
accessLevelRestricted
2023 129 0
Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 comparedThe journal of infectious diseases
accessLevelPublic
2023 113 65
Does menopause transition influence viral suppression and adherence in women living with HIV?Journal of acquired immune deficiency syndromes
accessLevelPublic
2023 82 20
Multicentric evaluation of a specific intrathecal anti-Treponema pallidum IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control studySexually transmitted infections
accessLevelRestricted
2023 169 0
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort StudyClinical infectious diseases
accessLevelPublic
2023 100 36
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Open forum infectious diseases
accessLevelPublic
2023 137 70
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19Open forum infectious diseases
accessLevelPublic
2023 118 87
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018The journal of antimicrobial chemotherapy
accessLevelPublic
2023 139 145
Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trialThrombosis research
accessLevelPublic
2023 315 66
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant RecipientsVaccines
accessLevelPublic
2023 88 86
Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)HIV medicine
accessLevelPublic
2022 144 103
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trialTrials
accessLevelPublic
2022 132 113
Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variantsFrontiers in microbiology
accessLevelPublic
2022 255 55
Cardiovascular risk assessment in people living with HIV compared to the general populationEuropean journal of preventive cardiology
accessLevelPublic
2022 219 114
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected IndividualsFrontiers in immunology
accessLevelPublic
2022 254 87
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 EpidemicsJournal of acquired immune deficiency syndromes
accessLevelPublic
2022 185 57
An Approach to Quantifying the Interaction between Behavioral and Transmission ClustersViruses
accessLevelPublic
2022 92 18
CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelPublic
2022 95 49
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in SwitzerlandPharmaceutics
accessLevelPublic
2022 68 76
Immunocompromised patients have been neglected in COVID-19 trials: a call for actionClinical microbiology and infection
accessLevelPublic
2022 71 73
Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional StudyJournal of immigrant and minority health
accessLevelPublic
2022 90 65
La variole du singe: Une nouvelle épidémie – réponses aux questions fréquentes dans la pratiquePrimary and Hospital Care
accessLevelPublic
2022 208 73
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimabLancet. Infectious diseases
accessLevelPublic
2022 116 183
Impact of Latent Tuberculosis on DiabetesThe journal of infectious diseases
accessLevelRestricted
2022 218 0
Accelerating investigation of new HIV drugs in pregnancy : advancing the research agenda from theory to actionJournal of the International AIDS Society
accessLevelPublic
2022 76 39
Use of Ritonavir-Boosted Nirmatrelvir in PregnancyClinical infectious diseases
accessLevelPublic
2022 101 16
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension periodAIDS
accessLevelPublic
2022 766 194
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe HypoxemiaJAMA
accessLevelRestricted
2022 169 0
How mHealth Can Contribute to Improving the Continuum of Care: A Scoping Review Approach to the Case of Human Immunodeficiency Virus in Sub-Saharan AfricaPublic health reviews
accessLevelPublic
2022 99 32
Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort StudyJournal of antimicrobial chemotherapy
accessLevelPublic
2022 92 48
A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort StudyThe journal of infectious diseases
accessLevelRestricted
2022 123 0
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trialsAIDS
accessLevelRestricted
2022 56 0
How the COVID-19 Pandemic Alters the Landscapes of the HIV and Tuberculosis Epidemics in South Africa: A Case Study and Future DirectionsEpidemiologia
accessLevelPublic
2022 82 124
VIH et Covid-19 : deux pandémies virales en interactionRevue médicale suisse
accessLevelPublic
2022 74 67
Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trialClinical and translational science
accessLevelPublic
2022 150 107
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort studyThe journal of antimicrobial chemotherapy
accessLevelRestricted
2022 100 0
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trialResearch and practice in thrombosis and haemostasis
accessLevelPublic
2022 245 245
Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virusOpen forum infectious diseases
accessLevelPublic
2022 90 92
Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative studyHIV medicine
accessLevelPublic
2022 361 131
Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approachThe journal of infectious diseases
accessLevelRestricted
2022 134 2
A highly virulent variant of HIV-1 circulating in the NetherlandsScience
accessLevelPublic
2022 192 53
Bas les masques, et après ?Revue médicale suisse
accessLevelPublic
2022 62 52
Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2022 211 277
Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort StudyThe Journal of infectious diseases
accessLevelPublic
2022 138 155
Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patientsBMC infectious diseases
accessLevelPublic
2022 139 68
Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS)HIV medicine
accessLevelPublic
2022 113 70
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)International journal of epidemiology
accessLevelRestricted
2022 259 0
Approaches to accelerating the study of new antiretrovirals in pregnancyJournal of the International AIDS Society
accessLevelPublic
2022 73 102
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trialBritish journal of clinical pharmacology
accessLevelRestricted
2021 214 0
Cyber harassment of female scientists will not be the new normThe Lancet Infectious Diseases
accessLevelPublic
2021 255 196
Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal SwabsFrontiers in Medicine
accessLevelPublic
2021 216 127
Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in EswatiniJournal of acquired immune deficiency syndromes
accessLevelPublic
2021 179 144
Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIVClinical infectious diseases
accessLevelRestricted
2021 184 0
Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort StudyOpen Forum Infectious Diseases
accessLevelPublic
2021 316 162
Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular RiskThe journal of infectious diseases
accessLevelRestricted
2021 244 9
Kaposi sarcoma in antiretroviral therapy-treated people with HIV: a wake-up call for research on human herpesvirus-8AIDS
accessLevelPublic
2021 259 219
Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatmentClinical infectious diseases
accessLevelPublic
2021 200 120
The role of Human Immunodeficiency Virus (HIV) asymptomatic status when starting antiretroviral therapy on adherence and treatment outcomes and implications for test and treat: the swiss HIV Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2021 158 0
VIH/sida - VIH au temps du Covid-19 : rencontre de deux pandémiesRevue médicale suisse
accessLevelPublic
2021 210 99
Nouveautés dans le diagnostic du VIHForum médical suisse
accessLevelPublic
2021 266 290
Caring for people living with HIV during the global coronavirus disease 2019 pandemicAIDS
accessLevelRestricted
2021 239 0
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2021 324 0
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in SwitzerlandPloS one
accessLevelPublic
2021 212 296
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIVAIDS
accessLevelPublic
2021 209 111
Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxisNature communications
accessLevelPublic
2021 81 10
Weight gain stopping/switch rules for antiretroviral clinical trialsAIDS
accessLevelPublic
2021 186 72
Prophylaxis for COVID-19: a systematic reviewClinical microbiology and infection
accessLevelPublic
2021 87 90
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequityThe journal of antimicrobial chemotherapy
accessLevelRestricted
2021 175 0
Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk groupClinical Infectious Diseases
accessLevelRestricted
2021 195 0
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialEClinicalMedicine
accessLevelPublic
2021 638 147
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort StudyAnnals of internal medicine
accessLevelRestricted
2021 208 0
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase InhibitorsClinical infectious diseases
accessLevelRestricted
2021 180 0
Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell TherapiesJournal of acquired immune deficiency syndromes
accessLevelRestricted
2021 173 0
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort StudyThe journal of infectious diseases
accessLevelPublic
2021 103 31
Impact of rosuvastatin on atherosclerosis in people with hiv at moderate cardiovascular risk: a randomised, controlled trialAIDS
accessLevelPublic
2021 671 209
Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with Human Immunodeficiency VirusClinical infectious diseases
accessLevelPublic
2021 167 136
The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort StudyJournal of clinical medicine
accessLevelPublic
2021 81 63
Possible link between anosmia and COVID-19: sniffing out the truthEuropean Archives of Oto-Rhino-Laryngology
accessLevelPublic
2020 195 164
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study : 1980-2018Antiviral therapy
accessLevelRestricted
2020 70 0
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelinesThe Lancet HIV
accessLevelPublic
2020 225 101
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristicsAmerican Heart Journal
accessLevelPublic
2020 254 104
Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2020 231 0
Clinicopathologic Aspects of a Papulovesicular Eruption in a Patient With COVID-19JAMA Dermatology
accessLevelRestricted
2020 312 0
Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK StudyJournal of the American College of Cardiology
accessLevelPublic
2020 409 146
Buyers' club : une alternative pour l'accès au traitement ?Revue médicale suisse
accessLevelPublic
2020 411 197
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort StudyThe journal of infectious diseases
accessLevelPublic
2020 210 190
Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIVPLoS biology
accessLevelPublic
2020 94 20
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costsSwiss Medical Weekly
accessLevelPublic
2020 505 355
Towards the real-time inclusion of sex- and age-disaggregated data in pandemic responsesBMJ global health
accessLevelPublic
2020 96 38
Mycobaterium fortuitum disseminated infection in an immunocompetent patient without predisposing factorsBMJ case reports
accessLevelRestricted
2020 181 0
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialPLoS medicine
accessLevelPublic
2020 220 181
Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case reportMedicine (Baltimore)
accessLevelPublic
2020 389 120
HIV and antiretroviral therapy-related fat alterationsNature Reviews. Disease Primers
accessLevelRestricted
2020 219 20
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profileHIV Medicine
accessLevelPublic
2020 407 186
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysisEClinicalMedicine
accessLevelPublic
2020 101 44
First reported case of Rothia dentocariosa spondylodiscitis in an immunocompetent patientIDCases
accessLevelPublic
2020 522 226
How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?HIV medicine
accessLevelPublic
2020 117 33
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral TherapyOpen Forum Infectious Diseases
accessLevelPublic
2020 234 115
Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT AngiographyOpen forum infectious diseases
accessLevelPublic
2020 137 84
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ARTNature Communications
accessLevelPublic
2020 259 70
Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patientsClinical Infectious Diseases
accessLevelRestricted
2020 365 3
C-terminus apoa-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formationAtherosclerosis
accessLevelRestricted
2020 247 0
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19 : initial assessmentJournal of the International AIDS Society
accessLevelPublic
2020 70 13
Dexamethasone and remdesivir: finding method in the COVID-19 madnessThe Lancet microbe
accessLevelPublic
2020 247 33
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingJournal of Acquired Immune Deficiency Syndromes
accessLevelPublic
2020 231 107
Cobicistat : A case of mislabelled drug-drug interaction risk?British journal of clinical pharmacology
accessLevelPublic
2020 69 13
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trialBMJ Open
accessLevelPublic
2020 266 103
VIH: prévention, traitement et perspectivesRevue médicale suisse
accessLevelPublic
2020 378 225
Impact of the M184V/I Mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV treatment-experienced patientsOpen Forum Infectious Diseases
accessLevelPublic
2019 300 242
Next-Generation Sequencing for the Diagnosis of Challenging Culture-Negative EndocarditisFrontiers in Medicine
accessLevelPublic
2019 386 235
Female Genital Schistosomiasis and HIV: Research Urgently Needed to Improve Understanding of the Health Impacts of This Important CoinfectionJournal of acquired immune deficiency syndromes
accessLevelRestricted
2019 186 0
Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African CountriesJMIR mhealth and uhealth
accessLevelPublic
2019 198 73
Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohortAtherosclerosis
accessLevelRestricted
2019 432 1
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against OsteoporosisOsteoporosis International
accessLevelRestricted
2019 356 1
Nouveautés dans le dépistage, la prévention et la prise en charge du VIH en 2018Revue médicale suisse
accessLevelPublic
2019 69 20
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsLancet
accessLevelRestricted
2019 93 0
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyThe lancet. HIV.
accessLevelPublic
2019 83 58
Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. WolfOsteoporosis international
accessLevelRestricted
2019 49 0
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherenceThe journal of antimicrobial chemotherapy
accessLevelRestricted
2019 82 0
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1New England Journal of Medicine
accessLevelPublic
2019 290 108
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017Journal of the International AIDS society
accessLevelPublic
2019 388 148
A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, noncommunicable diseases, and opportunistic diseasesThe Journal of Infectious Diseases
accessLevelRestricted
2019 352 0
Why do sub‐Saharan Africans present late for HIV care in Switzerland ?HIV medicine
accessLevelRestricted
2019 88 0
Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infectionThe Journal of Infectious Diseases
accessLevelRestricted
2019 296 0
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohortBMC infectious diseases
accessLevelPublic
2019 225 64
Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factorsF1000Research
accessLevelPublic
2019 255 98
Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active MetabolitesClinical Pharmacokinetics
accessLevelPublic
2018 732 765
Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisF1000Research
accessLevelPublic
2018 155 142
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohortAIDS
accessLevelRestricted
2018 183 0
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort StudyLiver International
accessLevelRestricted
2018 484 0
Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patientsJournal of Infection
accessLevelRestricted
2018 575 1
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensHIV Medicine
accessLevelPublic
2018 375 168
Expert consensus statement on the science of HIV in the context of criminal lawJournal of the International AIDS Society
accessLevelPublic
2018 128 437
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort StudyVirus Evolution
accessLevelPublic
2018 383 91
High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 InfectionClinical Infectious Diseases
accessLevelRestricted
2018 401 0
A buyers' club to improve access to hepatitis C treatment for vulnerable populationsSwiss Medical Weekly
accessLevelPublic
2018 1,229 446
Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination ScheduleClinical infectious diseases
accessLevelRestricted
2018 87 0
Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID StudyKidney International Reports
accessLevelPublic
2018 491 154
Traitements antirétroviraux : vers un allègement ?Revue médicale suisse
accessLevelPublic
2018 64 63
The cumulative impact of harm reduction on the swiss HIV epidemic: cohort study, mathematical model, and phylogenetic analysisOpen Forum Infectious Diseases
accessLevelPublic
2018 374 168
Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trialJournal of the International AIDS Society
accessLevelPublic
2018 129 40
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite PathogenicityMolecular Biology and Evolution
accessLevelPublic
2018 502 206
Will NNRTIs be driving forward again ?The lancet. HIV
accessLevelRestricted
2018 54 0
Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patientAnnals of Hematology
accessLevelRestricted
2018 398 0
Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO studyHIV Medicine
accessLevelPublic
2018 331 106
Time to overcome pretreatment HIV drug resistanceThe Lancet Infectious Diseases
accessLevelPublic
2018 392 219
Managing Advanced HIV Disease in a Public Health ApproachClinical infectious diseases
accessLevelPublic
2018 79 56
Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in MadagascarInternational journal of infectious diseases
accessLevelPublic
2018 206 108
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?HIV Medicine
accessLevelRestricted
2018 369 0
Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in SwitzerlandHIV Medicine
accessLevelRestricted
2018 602 0
Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative personsEuropean heart journal
accessLevelRestricted
2018 100 0
The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral TherapyClinical infectious diseases
accessLevelPublic
2018 55 13
Anti-inflammatory therapy in well controlled HIV infectionThe Lancet HIV
accessLevelRestricted
2018 435 0
Benefits and risks of rapid initiation of antiretroviral therapyAIDS
accessLevelPublic
2018 472 298
Tracing HIV-1 strains that imprint broadly neutralizing antibody responsesNature
accessLevelRestricted
2018 179 0
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activityThe Journal of experimental medicine
accessLevelPublic
2018 306 113
Universal test and treat and the HIV epidemic in rural South Africa : a phase 4, open-label, community cluster randomised trialThe lancet. HIV
accessLevelPublic
2018 75 78
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretroviralsMedicine (Philadelphia)
accessLevelPublic
2017 410 169
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general populationAIDS
accessLevelPublic
2017 411 232
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysiseLife
accessLevelPublic
2017 495 178
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisThe Lancet HIV
accessLevelRestricted
2017 441 0
Bone health in HIV and hepatitis B or C infectionsTherapeutic advances in musculoskeletal disease
accessLevelPublic
2017 545 290
Hepatitis delta-associated mortality in HIV/HBV-coinfected patientsJournal of Hepatology
accessLevelPublic
2017 427 514
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European studyJournal of Antimicrobial Chemotherapy
accessLevelRestricted
2017 417 0
Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort StudyHIV Medicine
accessLevelRestricted
2017 386 0
High prevalence of physical inactivity among patients from the Swiss HIV Cohort StudyAIDS Care
accessLevelPublic
2017 409 585
Human papillomavirus antibody response following HAART initiation among MSMAIDS
accessLevelRestricted
2017 425 0
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2017 393 0
Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort AnalysisClinical Infectious Diseases
accessLevelPublic
2017 407 200
Adverse events of raltegravir and dolutegravirAIDS
accessLevelPublic
2017 424 168
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)The Lancet HIV
accessLevelRestricted
2017 401 0
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort studyBMC Infectious Diseases
accessLevelPublic
2017 419 171
Blinded by Zika? A missed HIV diagnosis that resulted in optic neuropathy and blindness: a case reportBMC Research Notes
accessLevelPublic
2017 420 219
Mining for pairs: shared clinic visit dates identify steady HIV-positive partnershipsHIV Medicine
accessLevelRestricted
2017 446 0
Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort StudyOpen Forum Infectious Diseases
accessLevelPublic
2017 394 158
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialThe Lancet HIV
accessLevelRestricted
2017 415 0
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSMAIDS
accessLevelPublic
2017 590 362
The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular EventsJournal of acquired immune deficiency syndromes
accessLevelRestricted
2016 84 0
Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy : The Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2016 84 34
Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland comparedInternational journal of infectious diseases
accessLevelPublic
2016 512 157
Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventionsHepatology
accessLevelPublic
2016 702 290
Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest SwitzerlandSexually transmitted diseases
accessLevelRestricted
2016 67 0
Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence CountryJournal of Clinical Microbiology
accessLevelRestricted
2016 523 0
HIV-Positive-to-HIV-Positive Liver TransplantationAmerican journal of transplantation
accessLevelPublic
2016 664 404
Determinants of HIV-1 broadly neutralizing antibody inductionNature Medicine
accessLevelPublic
2016 562 410
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort StudyThe Journal of Infectious Diseases
accessLevelPublic
2016 419 230
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV InfectionThe journal of infectious diseases
accessLevelRestricted
2016 57 0
The 2014–2015 Ebola outbreak in West Africa: Hands OnAntimicrobial Resistance and Infection Control
accessLevelPublic
2016 537 229
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort AnalysisClinical Infectious Diseases
accessLevelRestricted
2016 678 1
HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort StudyClinical Infectious Diseases
accessLevelPublic
2016 516 179
Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and reviewNew microbes and new infections
accessLevelRestricted
2015 609 1
Increases in Condomless Sex in the Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2015 89 38
Corrigendum to "Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review" [New Microbes New Infect] 6 (2015) 1-4]New microbes and new infections
accessLevelRestricted
2015 503 0
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort StudyBMC infectious diseases
accessLevelPublic
2015 102 59
Hit me with your best shot: dolutegravir - a space in the next WHO guidelines ?AIDS
accessLevelRestricted
2015 79 0
Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in SwitzerlandAIDS
accessLevelRestricted
2015 90 0
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents : a systematic reviewClinical infectious diseases
accessLevelRestricted
2015 77 0
Is monotherapy maintenance the way forward ?The lancet. HIV
accessLevelPublic
2015 66 57
Reasons for late presentation to HIV care in SwitzerlandJournal of the International AIDS Society
accessLevelPublic
2015 71 31
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelPublic
2015 100 25
Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisalBMC public health
accessLevelPublic
2015 88 45
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective studyEuropean journal of clinical investigation
accessLevelPrivate
2015 603 0
The future role of CD4 cell count for monitoring antiretroviral therapyLancet. Infectious diseases
accessLevelRestricted
2015 506 0
Prise en charge du VIH/sida en 2015Revue médicale suisse
accessLevelPublic
2015 74 39
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected personsBMC gastroenterology
accessLevelPublic
2015 78 20
Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaAIDS
accessLevelPublic
2015 106 76
Evidence on the protective role of high-density lipoprotein (HDL) in HIV-infected individualsCurrent vascular pharmacology
2015 685 0
Syphilis: Diagnostik und BehandlungSwiss Medical Forum
accessLevelPublic
2015 384 851
Generating Evidence to Improve the Response to Neglected Diseases : How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management GuidancePLoS neglected tropical diseases
accessLevelPublic
2015 69 14
World Health Organization Guidelines on Postexposure Prophylaxis for HIV : Recommendations for a Public Health ApproachClinical infectious diseases
accessLevelRestricted
2015 58 0
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortalityAIDS
accessLevelRestricted
2015 75 0
Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRIDermatology
accessLevelRestricted
2015 765 1
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General PopulationOpen forum infectious diseases
accessLevelPublic
2015 602 248
Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disordersAIDS research and therapy
accessLevelPublic
2015 624 317
Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCVInternational journal of epidemiology
accessLevelPublic
2014 769 432
Disentangling human tolerance and resistance against HIVPLoS biology
accessLevelPublic
2014 664 339
Clinical significance of the CCR5delta32 allele in hepatitis CPloS one
accessLevelPublic
2014 581 229
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patientsAIDS
accessLevelRestricted
2014 567 0
Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literatureJournal of the International AIDS Society
accessLevelPublic
2014 583 448
AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to beJournal of the International AIDS Society
accessLevelPublic
2014 636 281
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patientsAIDS
accessLevelRestricted
2014 569 0
Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapyTM & IH. Tropical medicine and international health
accessLevelPublic
2014 611 511
Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort StudyClinical infectious diseases
accessLevelRestricted
2014 709 0
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activityAIDS research and therapy
accessLevelPublic
2014 735 942
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisAIDS
accessLevelRestricted
2014 491 0
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in ZambiaClinical infectious diseases
accessLevelPublic
2014 726 283
Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in SwitzerlandAmerican journal of epidemiology
accessLevelPublic
2014 866 55
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wideThe Journal of infectious diseases
accessLevelRestricted
2014 603 0
Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approachJournal of the International AIDS Society
accessLevelPublic
2014 619 1,374
Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backboneHIV clinical trials
accessLevelRestricted
2014 79 0
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort StudyAntimicrobial agents and chemotherapy
accessLevelPublic
2014 907 581
Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroonOpen forum infectious diseases
accessLevelPublic
2014 528 331
Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapyAIDS
accessLevelPublic
2014 811 634
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatmentAntimicrobial agents and chemotherapy
accessLevelRestricted
2014 145 0
Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysisAIDS
accessLevelRestricted
2014 555 2
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2014 980 349
Réplication cérébrale du VIH malgré une thérapie antirétrovirale efficace: impact clinique et prise en chargeRevue médicale suisse
accessLevelPublic
2014 802 439
Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infectionThe American journal of cardiology
accessLevelRestricted
2013 624 0
Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence : the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa : study protocol for a cluster randomised controlled trialTrials
accessLevelPublic
2013 106 18
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infectionThe Journal of infectious diseases
accessLevelRestricted
2013 650 0
Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysisAIDS
accessLevelRestricted
2013 592 0
HIV-infected women in Europe: gender-specific needs and challengesAntiviral therapy
2013 615 0
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort StudyAmerican journal of epidemiology
accessLevelRestricted
2013 669 0
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysisAIDS
accessLevelRestricted
2013 624 0
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2013 635 0
Clinical Course and Management of Iatrogenic Cushing's Syndrome after Co-Administration of Injected-Triamcinolone and Ritonavir: a Systematic ReviewJournal of Antivirals and Antiretrovirals
accessLevelPublic
2013 1,228 331
Les os des personnes infectées par le VIH sont-ils si fragiles?Revue médicale suisse
accessLevelRestricted
2013 625 0
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsPLoS computational biology
accessLevelPublic
2013 699 265
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosisPLOS genetics
accessLevelPublic
2013 927 631
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individualsPharmacogenetics and genomics
accessLevelRestricted
2013 660 0
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literatureAIDS
accessLevelRestricted
2013 633 0
La prophylaxie postexposition dans tous ses étatsRevue médicale suisse
accessLevelRestricted
2013 602 0
VIH/sida : une sélection des nouveautés les plus prometteuses en 2012Revue médicale suisse
accessLevelRestricted
2013 565 2
Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal womenOsteoporosis international
accessLevelPublic
2013 826 295
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot studyNeurology
accessLevelRestricted
2013 818 1
Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort StudyPloS one
accessLevelPublic
2013 616 572
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)Journal of acquired immune deficiency syndromes
accessLevelRestricted
2013 601 0
Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavirAIDS
accessLevelPublic
2013 573 359
Association of Alcohol Consumption and HIV Surrogate Markers in Participants of the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2013 570 0
Bénéfices d'un accompagnement psychologique des patients vivant avec le VIHRevue médicale suisse
accessLevelRestricted
2013 728 0
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trialLancet. Infectious diseases
accessLevelRestricted
2013 948 0
Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High FieldPloS one
accessLevelPublic
2013 806 1,163
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort studyThe Journal of infectious diseases
accessLevelRestricted
2013 645 0
Produits de comblement du visage : dispositifs médicaux ou médicaments ? Implication pour les patients VIH+ atteints de lipoatrophieRevue médicale suisse
accessLevelRestricted
2012 592 0
Efavirenz is not a known teratogenThe Pediatric infectious disease journal
accessLevelRestricted
2012 557 0
Expert reviews: who are they for?Expert opinion on pharmacotherapy
accessLevelRestricted
2012 568 0
Preferred antiretroviral drugs for the next decade of scale upJournal of the International AIDS Society
accessLevelPublic
2012 548 443
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infectionBritish journal of cancer
accessLevelPublic
2012 581 1,071
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patientAIDS
accessLevelPublic
2012 633 592
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settingsHIV/AIDS[1179-1373]
accessLevelPublic
2012 753 894
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavirAIDS
accessLevelRestricted
2012 614 0
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumoniaAIDS
accessLevelRestricted
2012 668 0
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosisAntimicrobial agents and chemotherapy
accessLevelPublic
2012 879 1,212
Buruli et VIH: une interaction complexe et peu étudiéeRevue médicale suisse
accessLevelRestricted
2012 515 0
Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infectionJournal of clinical microbiology
accessLevelPublic
2012 974 1,652
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccinePloS one
accessLevelPublic
2012 769 327
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensPloS one
accessLevelPublic
2012 640 273
VIH/SIDARevue médicale suisse
accessLevelRestricted
2012 530 1
Outcome of smoking cessation counselling of HIV-positive persons by HIV care physiciansHIV medicine
accessLevelRestricted
2012 594 0
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemicClinical infectious diseases
accessLevelRestricted
2012 560 0
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaborationInternational journal of epidemiology
accessLevelRestricted
2012 669 0
Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patientsHIV medicine
accessLevelRestricted
2012 720 0
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2012 633 0
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settingsBMC infectious diseases
accessLevelPublic
2012 624 440
Défis de la co-infection par le virus de l'hépatite C et le VIHRevue médicale suisse
accessLevelRestricted
2012 619 0
Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2012 634 1
Viral load monitoring in resource-limited settings: a medical and public health priorityAIDS
accessLevelRestricted
2012 530 1
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsPloS one
accessLevelPublic
2012 634 231
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011Clinical infectious diseases
accessLevelPublic
2012 632 557
Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infectionsAIDS
accessLevelPublic
2012 738 436
Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinicJournal of acquired immune deficiency syndromes
accessLevelRestricted
2011 75 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipientsHaematologica
accessLevelPublic
2011 1,048 601
Ageing with HIV : medication use and risk for potential drug-drug interactionsJournal of antimicrobial chemotherapy
accessLevelRestricted
2011 57 0
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexualsWorld journal of gastroenterology
accessLevelPublic
2011 943 646
Successful efavirenz dose reduction guided by therapeutic drug monitoringAntiviral therapy
accessLevelRestricted
2011 56 0
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisAIDS
accessLevelRestricted
2011 66 0
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center studyArthritis and rheumatism
accessLevelRestricted
2011 868 8
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and SwitzerlandPloS one
accessLevelPublic
2011 1,277 364
Co-infection tuberculose et VIH: enjeux thérapeutiquesRevue médicale suisse
accessLevelRestricted
2011 661 0
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study GroupClinical infectious diseases
accessLevelRestricted
2011 101 0
VIH/SIDA : nombreuses nouveautésRevue médicale suisse
accessLevelPublic
2011 73 116
A randomized crossover study to compare efavirenz and etravirine treatmentAIDS
accessLevelRestricted
2011 103 0
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settingsHIV/AIDS
accessLevelPublic
2011 746 547
The first decade of antiretroviral therapy in AfricaGlobalization and health
accessLevelPublic
2011 76 17
HIV treatment for preventionJournal of the International AIDS Society
accessLevelPublic
2011 67 24
Clinical relevance of cytomegalovirus viraemiaHIV medicine
accessLevelRestricted
2011 653 0
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteersAntimicrobial agents and chemotherapy
accessLevelRestricted
2010 634 0
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyAntiviral therapy
2010 567 0
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirPharmacogenetics and genomics
accessLevelRestricted
2010 702 0
Improving first-line antiretroviral therapy in resource-limited settingsCurrent opinion in HIV and AIDS
accessLevelRestricted
2010 554 0
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohortsAIDS
accessLevelRestricted
2010 545 0
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infectionThe Journal of infectious diseases
accessLevelPublic
2010 626 317
Reduction of missed appointments at an urban primary care clinic: a randomised controlled studyBMC family practice
accessLevelPublic
2010 679 396
Treatment of HIV infection with drugs for HSV-2 infectionLancet
accessLevelRestricted
2010 522 0
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort StudyBritish journal of cancer
accessLevelRestricted
2010 794 1
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countriesJAMA
accessLevelRestricted
2010 583 0
Optimizing HIV drug therapy
accessLevelPublic
2010 661 1,833
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapyHIV medicine
accessLevelRestricted
2010 624 0
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in CameroonBMC public health
accessLevelPublic
2010 647 246
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patientsAIDS
accessLevelRestricted
2010 595 0
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemiaClinical infectious diseases
accessLevelRestricted
2010 611 0
Hyaluronic acid injections to fill facial lipoatrophy in the context of a lipodystrophy syndrome associated with HIVDermatologica Helvetica
accessLevelPublic
2010 256 59
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trialHIV medicine
accessLevelRestricted
2010 582 0
Patient needs and point-of-care requirements for HIV load testing in resource-limited settingsThe Journal of infectious diseases
accessLevelRestricted
2010 583 0
Cognitive dysfunction in HIV patients despite long-standing suppression of viremiaAIDS
accessLevelRestricted
2010 915 1
When to start antiretroviral therapy in resource-limited settings: a human rights analysisBMC international health and human rights
accessLevelPublic
2010 625 365
Health perceptions of African HIV-infected patients and their physiciansPatient education and counseling
accessLevelRestricted
2010 649 0
A new era of antiretroviral drug toxicityAntiviral therapy
2009 592 0
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoringAIDS
accessLevelRestricted
2009 90 0
Education thérapeutique en maladie infectieuse : l'exemple de l'infection à VIHRevue médicale suisse
2009 648 0
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trialAIDS
accessLevelRestricted
2009 658 0
Safety and efficacy of once-daily nevirapine dosing: a multicohort studyAntiviral therapy
2009 653 0
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine : a nested case-control studyClinical infectious diseases
accessLevelRestricted
2009 73 0
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional studyThe Journal of infectious diseases
accessLevelRestricted
2009 596 0
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patientsAntiviral therapy
accessLevelRestricted
2009 57 0
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretroviralsDrug discovery today
accessLevelRestricted
2008 86 0
Dix ans de lipodystrophie (1998-2008) : un syndrome encore méconnuRevue médicale suisse
accessLevelPublic
2008 584 174
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in CameroonJournal of acquired immune deficiency syndromes
accessLevelRestricted
2008 74 0
The marriage of science and optimized HIV care in resource-limited settingsAIDS
accessLevelRestricted
2008 70 0
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switchingAIDS
accessLevelRestricted
2008 79 0
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapyHIV medicine
accessLevelRestricted
2008 79 0
Initial treatment for HIV infection--an embarrassment of richesThe New England journal of medicine
accessLevelRestricted
2008 602 0
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006HIV medicine
accessLevelRestricted
2008 606 0
10 Jahren Lipodystrophie (1998-2008): Die "Groupe Lipo" der Hôpitaux universitaires de Genève: Ein Beratungsangebot für VIH-Positive mit dem Lipodystrophie-SyndromeDermatologica Helvetica
accessLevelPublic
2008 234 32
Clinical update: adverse effects of antiretroviral therapyLancet
accessLevelRestricted
2007 624 0
HIV viral load monitoring in resource-limited regions: optional or necessary?Clinical infectious diseases
accessLevelRestricted
2007 623 1
Treating HIV in the developing world: getting ahead of the drug development curveDrug discovery today
accessLevelRestricted
2007 62 0
Generic fixed-dose combination antiretroviral treatment in resource-poor settings : multicentric observational cohortAIDS
accessLevelRestricted
2006 78 0
Field assessment of generic antiretroviral drugs : a prospective cohort study in CameroonAntiviral therapy
accessLevelRestricted
2005 89 0
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudineAIDS
accessLevelRestricted
2004 69 0
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapyClinical infectious diseases
accessLevelRestricted
2004 66 0
First-line and second-line antiretroviral therapyLancet
accessLevelRestricted
2004 65 0
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialLancet
accessLevelRestricted
2004 82 0
HIV drug resistanceNew England journal of medicine
accessLevelPublic
2004 52 50
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapyAIDS
accessLevelRestricted
2003 542 0
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans FrontièresAIDS
accessLevelRestricted
2003 53 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack